Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Citigroup Inc.

Citigroup Inc. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.2% in the 2nd quarter, HoldingsChannel reports. The fund owned 184,246 shares of the biopharmaceutical company’s stock after acquiring an additional 374 shares during the quarter. Citigroup Inc.’s holdings in Regeneron Pharmaceuticals were worth $96,729,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in REGN. Citizens Financial Group Inc. RI lifted its stake in shares of Regeneron Pharmaceuticals by 237.4% in the second quarter. Citizens Financial Group Inc. RI now owns 2,659 shares of the biopharmaceutical company’s stock valued at $1,396,000 after purchasing an additional 1,871 shares during the period. Westwood Holdings Group Inc. increased its holdings in Regeneron Pharmaceuticals by 17.0% in the second quarter. Westwood Holdings Group Inc. now owns 13,556 shares of the biopharmaceutical company’s stock valued at $7,117,000 after buying an additional 1,974 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Regeneron Pharmaceuticals by 5.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,469 shares of the biopharmaceutical company’s stock valued at $13,371,000 after acquiring an additional 1,409 shares during the period. Grandfield & Dodd LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.0% during the 2nd quarter. Grandfield & Dodd LLC now owns 35,205 shares of the biopharmaceutical company’s stock worth $18,483,000 after acquiring an additional 1,998 shares in the last quarter. Finally, First Western Trust Bank grew its holdings in shares of Regeneron Pharmaceuticals by 6.4% in the 2nd quarter. First Western Trust Bank now owns 545 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 33 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on REGN. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Jefferies Financial Group raised their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 29th. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, UBS Group lifted their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $772.76.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $725.34 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The stock has a fifty day moving average of $605.06 and a two-hundred day moving average of $572.50. The company has a market capitalization of $76.23 billion, a price-to-earnings ratio of 17.37, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $800.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business earned $12.46 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.